Nippon Shinyaku Licenses Leukemia Drug Marketing Rights In Korea To Korean Company
This article was originally published in PharmAsia News
Executive Summary
Nippon Shinyaku signed a license agreement Dec. 4 with Korean drug seller BL&H and provided the company exclusive marketing rights to acute promyelocytic leukemia drug Trisenox (arsenic trioxide) in South Korea. Nippon Shinyaku obtained the manufacturing and marketing rights in Japan and Korea from U.S. drug maker Cephalon in 2002, and started manufacturing and marketing it in Japan in 2004, but the company has not marketed the drug in South Korea. Payment details were not disclosed. BL&H plans to market the drug in spring 2010. (Click here for more - Japanese language
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.